IP Library Granted Patent US 10,681,932
Granted Patent B2
US 10,681,932 · App. 15/591,389 · Granted Jun 16, 2020

Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases

Inventor: Claude Vincent (Bordeaux, FR)
Assignee: INTERNATIONAL NUTRITION RESEARCH COMPANY
A23L33/135A23P10/30A61K9/00A61K9/0053A61K35/74A61P3/00A61P3/04C12N1/20C12R1/01C12R1/145A61K35/00A61K45/06A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,681,932
App. No.
15/591,389
Granted
Jun 16, 2020
Kind
B2
Abstract

The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.

Claims (11)

1. A method of increasing the population of an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) comprising the 16S rRNA sequence of SEQ ID NO: 1 in the intestinal microbiome of a patient, wherein the method comprises administering to the patient a daily unit dose of 10 4 to 10 12 of live, inheritable, Gram-negative, strictly anaerobic and commensal bacteria of the family Christensenellaceae belonging to the OTU comprising a 16S rRNA sequence having more than 97% similarity to SEQ ID NO: 1, wherein the bacteria are administered orally or rectally.

2. The method of claim 1 , wherein said bacteria of the family Christensenellaceae comprise the 16S rRNA sequence of SEQ ID NO: 1.

3. The method of claim 1 , wherein the patient has excess body weight or obesity.

4. The method of claim 1 , wherein the patient has a cardiometabolic disease and/or an inflammatory bowel disease.

5. The method of claim 1 , wherein the patient has metabolic syndrome, pre-diabetes, or diabetes.

6. The method of claim 1 , wherein the patient has vascular disease, cardiac disease, atherosclerosis, hyperlipidemia, or hyperglycemia.

7. The method of claim 1 , wherein the patient has Non-Alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease (NAFLD) and/or Crohn's disease.

8. The method of claim 1 , wherein the patient has hypertriglycemia.

9. The method of claim 1 , wherein the patient has a Body Mass Index (BMI) greater than 25.

10. The method of claim 1 , wherein the patient has a Body Mass Index (BMI) greater than 30.

11. The method of claim 1 , further comprising a balanced diet and/or caloric restriction.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2023
From: YSOPIA BIOSCIENCES
To: VERB BIOTICS
Reel/Frame 065669/0673 →
CHANGE OF NAME Recorded Nov 16, 2023
From: LNC THERAPEUTICS
To: YSOPIA BIOSCIENCES
Reel/Frame 065609/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: INTERNATIONAL NUTRITION RESEARCH COMPANY
To: LNC THERAPEUTICS
Reel/Frame 065568/0013 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 042868 FRAME: 0621. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Aug 4, 2017
From: VINCENT, CLAUDE
To: INTERNATIONAL NUTRITION RESEARCH COMPANY
Reel/Frame 043447/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2017
From: VNCENT, CLAUDE
To: INTERNATIONAL NUTRITION RESEARCH COMPANY
Reel/Frame 042868/0621 →
Priority Claims (1)
FR 17 70237 · Mar 10, 2017 · national
Continuity (1)
Related Publication 20180255819A1 · Sep 13, 2018